On-Demand Event

Highlights from the Latest ODYSSEY OUTCOMES Data: The Role of PCSK9 Inhibition Post-ACS

Original air date:
Wednesday, February 13, 2019

Running time: 59:33 minutes


Jean Grégoire, MD, FRCPC, FACC, FCCS, FACP
Paul Poirier, MD, PhD, FRCPC, FCCS, FACC, FAHA
George Thanassoulis, MD, BSc(Hon), MSc, FRCPC

Learning Objectives:

  • Review highlights of high CV risk (post ACS) patient profiles and the role and place of PCSK9i alirocumab in their treatment pathway
  • Discuss the latest ODYSSEY OUTCOMES data and subsequent sub-analysis
  • Describe the urgency to treat specific high CV risk patient profiles

Language: English

Therapeutic areas: Cardiology/Vascular Disease, Internal Medicine